Journey Medical Past Earnings Performance
Past criteria checks 0/6
Journey Medical's earnings have been declining at an average annual rate of -32.6%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 15.7% per year.
Key information
-32.6%
Earnings growth rate
-23.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 15.7% |
| Return on equity | -18.9% |
| Net Margin | -4.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Journey Medical Corporation (NASDAQ:DERM) Not Doing Enough For Some Investors As Its Shares Slump 31%
Mar 11
Journey Medical Corporation's (NASDAQ:DERM) 33% Dip In Price Shows Sentiment Is Matching Revenues
Jan 18Journey Medical Corporation's (NASDAQ:DERM) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Nov 10US$12.00: That's What Analysts Think Journey Medical Corporation (NASDAQ:DERM) Is Worth After Its Latest Results
May 12Revenue & Expenses BreakdownBeta
How Journey Medical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 79 | -4 | 44 | 8 |
| 30 Sep 23 | 80 | -12 | 48 | 10 |
| 30 Jun 23 | 61 | -39 | 54 | 11 |
| 31 Mar 23 | 63 | -38 | 58 | 12 |
| 31 Dec 22 | 74 | -30 | 59 | 11 |
| 30 Sep 22 | 75 | -41 | 61 | 9 |
| 30 Jun 22 | 79 | -41 | 56 | 7 |
| 31 Mar 22 | 76 | -46 | 48 | 18 |
| 31 Dec 21 | 63 | -44 | 40 | 17 |
| 30 Sep 21 | 59 | -20 | 31 | 15 |
| 30 Jun 21 | 49 | -9 | 26 | 14 |
| 31 Mar 21 | 45 | 4 | 23 | 0 |
| 31 Dec 20 | 45 | 5 | 22 | 0 |
| 31 Dec 19 | 35 | 4 | 19 | 0 |
Quality Earnings: DERM is currently unprofitable.
Growing Profit Margin: DERM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DERM is unprofitable, and losses have increased over the past 5 years at a rate of 32.6% per year.
Accelerating Growth: Unable to compare DERM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DERM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).
Return on Equity
High ROE: DERM has a negative Return on Equity (-18.93%), as it is currently unprofitable.